These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 36651055)

  • 21. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
    Lakshman A; Kumar SK
    Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequence not salvage.
    Sborov DW; Fortuna GG; Hayden PJ
    Br J Haematol; 2024 May; 204(5):1590-1592. PubMed ID: 38563345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma.
    Hansen DK; Dhakal B; Hamadani M; Dingli D; Jain T; Huff CA; Janakiram M; Liu YH; De Braganca KC; Lodowski N; Sander J; Okorozo P; McFarland L; Perciavalle M; Huo S; Qureshi ZP; Patel KK
    Front Immunol; 2024; 15():1405452. PubMed ID: 38915401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma.
    Strassl I; Podar K
    Expert Opin Drug Discov; 2024 Apr; 19(4):377-391. PubMed ID: 38369760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
    Davis JA; Shockley A; Hashmi H
    J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis.
    Wu W; Zhou Y; Wang Y; Keramat SA; Balasooriya NN; Zhao Z; Yang Y; Comans T; Dong H
    Appl Health Econ Health Policy; 2023 Sep; 21(5):773-783. PubMed ID: 37356080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cilta-cel OK'd for Multiple Myeloma.
    Cancer Discov; 2022 May; 12(5):1176. PubMed ID: 35491644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial.
    McGarvey N; Ung B; Carattini T; Imanak K; Lee A; Campbell TB; Patwardhan P
    Adv Ther; 2023 Oct; 40(10):4626-4638. PubMed ID: 37597153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma.
    Jagannath S; Joseph N; Crivera C; Kharat A; Jackson CC; Valluri S; Cost P; Phelps H; Slowik R; Klein T; Smolen L; Yu X; Cohen AD
    Oncol Ther; 2023 Jun; 11(2):263-275. PubMed ID: 37014590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
    Martin T; Usmani SZ; Schecter JM; Roccia T; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Pacaud L; Garrett A; Bartlett M; Haltner A; Van Sanden S; Diels J; Valluri S; Samjoo IA
    Curr Med Res Opin; 2023 Jan; 39(1):81-89. PubMed ID: 36271807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Next-Generation Chimeric Antigen Receptor T-cells.
    Yi D; Gergis M; Hsu J; Yang Y; Bi X; Aljurf M; Gergis U
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):117-121. PubMed ID: 36537905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients.
    Sanoyan DA; Seipel K; Bacher U; Kronig MN; Porret N; Wiedemann G; Daskalakis M; Pabst T
    BMC Cancer; 2023 Apr; 23(1):345. PubMed ID: 37061680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
    Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
    Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
    Martin T; Usmani SZ; Berdeja JG; Agha M; Cohen AD; Hari P; Avigan D; Deol A; Htut M; Lesokhin A; Munshi NC; O'Donnell E; Stewart AK; Schecter JM; Goldberg JD; Jackson CC; Yeh TM; Banerjee A; Allred A; Zudaire E; Deraedt W; Olyslager Y; Zhou C; Pacaud L; Madduri D; Jakubowiak A; Lin Y; Jagannath S
    J Clin Oncol; 2023 Feb; 41(6):1265-1274. PubMed ID: 35658469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of CAR T-Cell Therapy in Multiple Myeloma: A Canadian Perspective.
    Shih SC; Bhella S
    Curr Oncol; 2024 Jul; 31(7):3949-3967. PubMed ID: 39057164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison.
    Bar N; Diels J; van Sanden S; Mendes J; Hernando T; Burnett H; Cost P; Schecter JM; Lendvai N; Patel N; Ishida T; Er J; Harrison SJ; Lopez-Muñoz N
    Curr Med Res Opin; 2024 Sep; 40(9):1597-1603. PubMed ID: 39129504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.
    Lin Y; Qiu L; Usmani S; Joo CW; Costa L; Derman B; Du J; Einsele H; Fernandez de Larrea C; Hajek R; Ho PJ; Kastritis E; Martinez-Lopez J; Mateos MV; Mikhael J; Moreau P; Nagarajan C; Nooka A; O'Dwyer M; Schjesvold F; Sidana S; van de Donk NW; Weisel K; Zweegman S; Raje N; Otero PR; Anderson LD; Kumar S; Martin T;
    Lancet Oncol; 2024 Aug; 25(8):e374-e387. PubMed ID: 38821074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.
    Weisel K; Krishnan A; Schecter JM; Vogel M; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Yalniz F; Nesheiwat T; Van Sanden S; Diels J; Valluri S; Usmani SZ; Berdeja JG; Jagannath S; Martin T
    Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):690-701. PubMed ID: 35764490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative Effectiveness Research for CAR-T Therapies in Multiple Myeloma: Appropriate Comparisons Require Careful Considerations of Data Sources and Patient Populations.
    Shah N; Sussman M; Crivera C; Valluri S; Benner J; Jagannath S
    Clin Drug Investig; 2021 Mar; 41(3):201-210. PubMed ID: 33598857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.
    Lee DH; Kumar A; Mohammed T; Peres LC; Alsina M; Bachmeier C; Blue BJ; Brayer J; Chandrasekhar S; Grajales Cruz A; De Avila G; Elmariah H; Faramand R; Freeman C; Jain M; Khadka S; Khimani F; Liu H; Nishihori T; Oswald LB; Castaneda Puglianini OA; Shain KH; Smith E; Baz RC; Locke FL; Oliveira GH; Alomar M; Hansen DK
    Blood Adv; 2023 Aug; 7(16):4247-4257. PubMed ID: 37307173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.